09.15am Wednesday 19 June, Boothroyd Room, Portcullis
House
On Wednesday 19th June, the Committee on Exiting the European
Union continues a series of sessions examining the impact of a
no-deal departure on key sectors of the UK economy. It’s part of
the Committee’s over-arching inquiry examining the progress of
the UK’s negotiations on EU withdrawal.
In its twelfth report,
published in January, the Committee emphasised that a no-deal
departure has remained the legal default since the UK triggered
Article 50 in March 2017, but found that Government preparations
for such a scenario have been inconsistent in nature. The
agreement of an extension to the Article 50 process until 31
October does not alter the legal situation.
In this session, the Committee will hear firstly from
associations representing manufacturers of pharmaceuticals and
chemicals; followed by representatives from higher education and
research bodies. The Committee is expected to focus on what
impact the agreement of an extension has had on their sectors,
what a no-deal scenario would look like in practice, and how the
continuing uncertainty has affected their ability to plan for the
various possible outcomes. The Committee will also assess the
quality of preparations made ahead of the initial March 29
deadline and the lessons learned as we approach the 31 October
deadline.
Witnesses:
From 09.15am, Wednesday 19 June:
- Steve
Bates, Chief Executive, BioIndustry Association
-
Nishma Patel, Chemicals Policy Director, Chemical Industries
Association
- Martin
Sawer, Executive Director, Healthcare Distribution Association
From approx. 10.15am:
-
Vivienne Stern, Director, Universities UK International
-
Professor Tim Wheeler, International Director, UK Research and
Innovation
- Dr Beth
Thompson MBE, Head of UK and EU Policy, Wellcome Trust
